Lilly Unveils SGD$42M Digital Health Innovation Hub In Singapore

Lilly Digital Health and its subsidiary, the Lilly Centre for Clinical Pharmacology (LCCP), have announced a SGD$42 million digital health innovation hub in Singapore. The initiative, supported by the Singapore Economic Development Board (EDB), aims to advance AI-powered health technologies as part of a five-year plan. The hub will utilize Lilly’s Magnol.AI platform, designed to process wearable sensor data and enable real-time AI-driven research, boosting accuracy and efficiency in digital health studies.

Goh Wan Yee, senior VP at EDB, emphasized that the hub aligns with Singapore’s National AI Strategy 2.0 to drive biomedical AI innovation and accelerate global clinical development. A unique feature of the hub is a smart toilet, equipped with pressure sensors to monitor clinical trial participants’ usage automatically, aiding researchers in evaluating medication effects.

Lilly has also been expanding its focus on advanced digital health. In September, the company partnered with Genetic Leap to develop RNA-targeted AI therapeutics. Previously, Lilly collaborated with diabetes management companies, including Dexcom and Welldoc, to integrate its Tempo Pen and Smart Button into digital platforms, advancing patient care and data sharing. These efforts highlight Lilly’s commitment to leveraging AI and digital tools to enhance clinical research and healthcare delivery.

Click here to read the original news story.